<DOC>
	<DOCNO>NCT00999206</DOCNO>
	<brief_summary>A phase 3 study obtain additional safety immunogenicity data Solvay 's cell-derived seasonal trivalent subunit influenza vaccine adult elderly subject without significant illness demonstrate consistency immunogenicity three lot vaccine , comparison cell-derived vaccine Solvay 's egg-derived vaccine include assessment non-inferior immunogenicity</brief_summary>
	<brief_title>Study Measuring Safety , Immunogenicity Lot Consistency Cell Derived Influenza Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria 1 . Female male subject &gt; = 18 year age ( adults &gt; = 18 &lt; =60 year age elderly &gt; = 61 year age ) . 2 . Willing able give inform consent protocol procedure perform . 3 . Able adhere visit schedule protocol require study procedure . 4 . Being good health determine medical history , physical examination clinical judgment investigator ( subject may underlie illness hypertension , diabetes , ischemic heart disease hypothyroidism , long disease well control . If medication condition , medication dose must stable least 3 month precede study vaccination ) . Exclusion Criteria 1 . Influenza vaccination laboratory confirm influenza infection within six month precede date study vaccination plan influenza vaccination three week study vaccination ( i.e . study Day 1 study Day 22 ) . 2 . Presence significant condition may prohibit inclusion determine Investigator . 3 . A serious adverse reaction previous ( influenza ) vaccination . 4 . A history GuillainBarr√© syndrome . 5 . Known allergic constituent study vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Vaccine</keyword>
	<keyword>CHMP criterion</keyword>
</DOC>